Literature DB >> 6395799

Examination of gram-negative bacilli from meningitis patients who failed or relapsed on moxalactam therapy.

R H Eng, C Cherubin, S M Smith, F Buccini.   

Abstract

One Salmonella and four Escherichia coli isolates from patients with bacterial meningitis who had responded slowly, relapsed, or failed to respond to monotherapy with moxalactam were examined. For purposes of comparison, an E. coli isolate from one patient who had responded promptly to therapy was also studied. On testing, moxalactam had higher MICs and MBCs (two to four times) than cefotaxime or ceftriaxone for all isolates; the rates of killing of the isolates were dependent on the antibiotic concentrations used. At comparable multiples of the MIC, these isolates were generally killed more slowly by moxalactam than by cefotaxime or ceftriaxone. In addition, a reduction of 3 in the logarithm of the number of CFU per milliliter could be attained at far lower concentrations with cefotaxime or ceftriaxone than with moxalactam. The degree of concentration-related killing of bacteria produced by the beta-lactams appeared to correlate with the clinical responses of the patients. Furthermore, real differences appeared to exist among the third-generation cephalosporins, which were not evident by the MIC and MBC points alone but were evident in the concentration-related killing curves: Determination of a reduction of 3 in the logarithm of the number of CFU per milliliter after a 6-h incubation is suggested as the criterion for the screening of antibiotics for the therapy for gram-negative bacillary meningitis.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6395799      PMCID: PMC180038          DOI: 10.1128/AAC.26.6.850

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  Relapse of gram-negative bacillary meningitis after cefotaxime therapy.

Authors:  R W Bradsher
Journal:  JAMA       Date:  1982-09-10       Impact factor: 56.272

2.  Designing appropriate therapy in the treatment of gram-negative bacillary meningitis.

Authors:  M L Corrado; M E Gombert; C E Cherubin
Journal:  JAMA       Date:  1982-07-02       Impact factor: 56.272

3.  Inoculum effect of new beta-lactam antibiotics on Pseudomonas aeruginosa.

Authors:  R H Eng; S M Smith; C Cherubin
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

4.  Treatment of gram-negative bacillary meningitis: role of the new cephalosporin antibiotics.

Authors:  C E Cherubin; M L Corrado; S R Nair; M E Gombert; S Landesman; G Humbert
Journal:  Rev Infect Dis       Date:  1982 Sep-Oct

5.  Mode of action of ceftazidime: affinity for the penicillin-binding proteins of Escherichia coli K12, Pseudomonas aeruginosa and Staphylococcus aureus.

Authors:  M V Hayes; D C Orr
Journal:  J Antimicrob Chemother       Date:  1983-08       Impact factor: 5.790

6.  Clinical evaluation of moxalactam: evidence of decreased efficacy in gram-positive aerobic infections.

Authors:  W Salzer; P S Pegram; C E McCall
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

7.  Moxalactam therapy for gram-negative bacillary meningitis.

Authors:  J J Rahal
Journal:  Rev Infect Dis       Date:  1982 Nov-Dec

8.  Moxalactam penetration into cerebrospinal fluid in patients with bacterial meningitis.

Authors:  J Modai; M Wolff; J Lebas; A Meulemans; C Manuel
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191

9.  Pharmacokinetics and cerebrospinal fluid penetration of moxalactam in children with bacterial meningitis.

Authors:  S L Kaplan; E O Mason; H Garcia; S J Kvernland; E M Loiselle; D C Anderson; A A Mintz; R D Feigin
Journal:  J Pediatr       Date:  1981-01       Impact factor: 4.406

10.  Clinical evaluation of a new broad-spectrum oxa-beta-lactam antibiotic, moxalactam, in neonates and infants.

Authors:  U B Schaad; G H McCracken; N Threlkeld; M L Thomas
Journal:  J Pediatr       Date:  1981-01       Impact factor: 4.406

View more
  12 in total

1.  Pharmacodynamics, a tool for a better use of antibiotics?

Authors:  F Crokaert
Journal:  Intensive Care Med       Date:  2001-02       Impact factor: 17.440

2.  Evaluation of two methods for overcoming the antibiotic carry-over effect.

Authors:  R H Eng; S M Smith; C E Cherubin; E N Tan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-01       Impact factor: 3.267

3.  A pharmacodynamic model for the action of the antibiotic imipenem on Pseudomonas aeruginosa populations in vitro.

Authors:  P H Berg; E O Voit; R L White
Journal:  Bull Math Biol       Date:  1996-09       Impact factor: 1.758

4.  [Rational parameters in the treatment of bacterial meningitis with modern cephalosporins].

Authors:  O Brückner; M Trautmann
Journal:  Infection       Date:  1987       Impact factor: 3.553

Review 5.  Cephalosporins in the treatment of meningitis.

Authors:  H C Neu
Journal:  Drugs       Date:  1987       Impact factor: 9.546

6.  Cefotaxime in the treatment of meningitis.

Authors:  C E Cherubin; J LeFrock
Journal:  Infection       Date:  1985       Impact factor: 3.553

7.  Comparative in vitro pharmacodynamics of imipenem and meropenem against Pseudomonas aeruginosa.

Authors:  R White; L Friedrich; D Burgess; D Warkentin; J Bosso
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

8.  Elimination of quinolone antibiotic carryover through use of antibiotic-removal beads.

Authors:  R A Zabinski; A J Larsson; K J Walker; S S Gilliland; J C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

9.  Single daily dosing of antibiotics: importance of in vitro killing rate, serum half-life, and protein binding.

Authors:  G Potel; N P Chau; B Pangon; B Fantin; J M Vallois; F Faurisson; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

Review 10.  Cefotaxime optimal dosage in adult patients. A reappraisal.

Authors:  A Simon; C A d'Aubrac; C Safran; C Carbon
Journal:  Drugs       Date:  1988       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.